Nitrogen mustard (mustine hydrochloride) has been used in the treatment of lung cancer for 20 years. Lynch, Ware, and Gaensler (1950) , Kent and Reh (1950) , Levine and Weisberger (1955) , Hatch, Bradford, and Ochsner (1956) , and Bass (1960) have described their experience with this cytotoxic agent and have reported symptomatic improvement in many patients, but little or no prolongation of life. Since 1958, when cyclophosphamide was synthesized, it has been widely used for malignant disease, including lung cancer, both palliatively in advanced inoperable disease (Spear and Patno, 1962; Braun-Wotke, 1963) , and as cover for operation in patients with less-advanced disease (Poulsen, 1962 (Poulsen, , 1963 .
Present Investigation
Our primary aim was to assess the objective evidence of improvement in patients with bronchial carcinoma treated with nitrogen mustard and cyclophosphamide and to compare the results of the two agents. The secondary aim was to assess the effect of early " follow-up " treatment on the survival time in the patients who had improved.
Selection of Patients.-The series ran for two years. At first all patients presenting with bronchial carcinoma at two chest clinics were included. After a short time patients who were suitable for operation were excluded because it was feared that cytotoxic therapy might be lowering the pulmonary diffusing capacity. Later investigations did not confirm this suspicion. There were 88 men and 9 women, and alternate male patients were given nitrogen mustard and cyclophosphamide, except at one peripheral hospital where it was difficult to manage intravenous nitrogen-mustard drips and all five male patients had cyclophosphamide. All female patients had nitrogen mustard.
Diagnosis. (Table I) . This difference, although suggestive of a greater benefit from cyclophosphamide, does not reach the 5% level of significance (X2=2.45). The dosage was probably not entirely comparable, as a greater fall in the white blood count tended to occur on the cyclophosphamide regimen than with the nitrogen mustard (Table II) and a larger dose of the latter might well have been tolerated, with an increase in the number of favourable responses. It has often been stated that nitrogen mustard does not prolong life in bronchial carcinoma (Bass, 1960) . Grenville-Mathers and Trenchard (1964) were unable to show that patients treated with cyclophosphamide survived two months longer than a control group. Certainly it is very difficult to show any prolongation statistically because of the extreme variability of the natural history of the disease and because of the brevity of most of the remissions with treatment ; but in patients who experience rapid relief of severe bone pain, vena-caval obstruction, and severe dysphagia, with remission occasionally for periods of up to six months or more, it must surely be accepted that some prolongation of life has been achieved.
It has been suggested that regression occurs only in secondary gland masses and secondary deposits and not in the primary tumour. This has not been our experience, as many primary tumours have shown undoubted regression both radiologically and bronchoscopically.
Some authorities believe that worth-while remission can be obtained only if the dosage of the cytotoxic agent is sufficient to cause marked leucopenia. Our own findings (Table II) do not support this contention. Striking symptomatic and objective response not infrequently occurs after a few doses of cyclophosphamide or even one dose of nitrogen mustard, and we do not believe that the response of the tumour and that of the bonemarrow are closely related. Flavell (1962) believes that any improvement with cytotoxic drugs of the nitrogen-mustard group is due to supportive antibiotics or steroids, but careful observation and assessment of the results of treatment in large numbers of patients without these supportive measures does not confirm this view. The patients in this series were treated with prednisone and Durabolin in view of the suggestion that these preparations safeguard the bone-marrow, and antibiotics were given only if they appeared to be essential.
The "follow-up " treatment was carried out to see whether x-ray therapy given to a tumour already in a state of partial remission from cytotoxic therapy resulted in unusually long remissions as compared with further intravenous and pulmonary-artery-perfusion therapy. After two years there were two survivors out of 12 patients who received follow-up radiotherapy, whereas 12 patients who had not improved on preliminary treatment had x-ray therapy later for various reasons and none of them survived 18 months. These groups are not strictly comparable and the numbers are small, so the difference may well be due to chance. Alternatively, a summation effect between the two treatments might be present or the response to the cytotoxic drugs could simply have occurred in tumours with parallel x-ray sensitivity.
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After more than two years there is one survivor out of four patients who underwent surgical resection after improving with preliminary treatment, whereas five out of eight having surgery without preliminary improvement survived two years and three are still alive. Again this difference could be pure chance. It could indicate that preliminary improvement on cytotoxic drugs was of no advantage or was harmful; but it was probably at least in part due to the fact that improvement with cytotoxic drugs occurred in patients with more rapidly growing and metastasizing tumours, which were therefore less amenable to curative resection.
The pulmonary-artery-perfusion group was planned because of a remarkable result that occurred previously in one out of 25 patients treated in this way. He was a 52-year-old man who at thoracotomy was found to have an advanced oat-cell growth invading the main vessels. Three weeks later he was given one dose of 17.5 mg. of nitrogen mustard by drip into the right main pulmonary artery. The next day he felt much better, and five days later the chest x-ray picture showed marked reduction in the shadowing due to the growth. Two weeks later the x-ray appearance had returned to normal and bronchoscopy confirmed the apparent complete resolution of the neoplasm. Four further perfusions were carried out during the next year and he remained well and at work for this period. Early recurrence was first suspected after 16 months, and deep x-ray therapy was given after 20 months. He survived for two and a half years.
One patient in the present series treated by pulmonary-artery perfusion with cyclophosphamide survived over 18 months, but this was a case of squamous-cell carcinoma and may well have been naturally slow-growing. There were no other responses worthy of remark.
The place of cytotoxic-drug therapy in the treatment of carcinoma of the bronchus remains controversial. The present series suggests that in about 50% of patients the tumour will recede to some extent during high-dosage treatment with cyclophosphamide. Poulsen's (1962 Poulsen's ( , 1963 findings of a higher one-year survival rate in patients with operable squamous-cell carcinomas treated with pre-operative and post-operative cyclophosphamide than in a controlled group having surgery alone encourages further research on these lines in the early cases.
With advanced disease the remissions are usually short, ranging from two to six months, but often they are worth while from the point of view of relief of distressing symptoms. It remains to be seen whether better results can be obtained with maintenance therapy or the combination of two or more different agents, and whether, when combined with x-ray therapy, summation or sensitizing effects can be obtained.
Summary
Ninety-seven patients with bronchial carcinoma were treated with nitrogen mustard or cyclophosphamide. Of those treated with cyclophosphamide 51% responded favourably as judged by the objective evidence, compared with 33 % of those receiving nitrogen mustard, but the limits of tolerance of nitrogenmustard dosage may not have been reached. " Follow-up" treatment of patients who had improved was carried out with x-ray therapy, further intravenous injections, or pulmonaryartery cytotoxic perfusion.
On immunogenetical grounds the foetus may be regarded as a homograft upon the mother, which, for reasons that are only poorly understood, escapes the usual fate of a homograft and remains unrejected. It seems possible, however, that some, perhaps most, early spontaneous abortions might be a specialized example of homograft rejection. Since a large number of foetuses expelled in such abortions are abnormalfor example, Moir (1964)-a non-toxic immunosuppressive drug might, on this idea, permit a malformed foetus to go to term that would otherwise have aborted. Most immunosuppressive drugs are, however, acutely toxic and their performance in preventing homograft rejection has not been an unqualified success.
Thalidomide is known to be relatively non-toxic (Somers, 1960) . If it also had immunosuppressive properties this would at once provide another aspect to explanations of its teratogenic action, and, at the same time, make it of considerable interest to those who seek to modify homograft rejection. To test whether it had any immunosuppressive properties its effect on the survival of mouse-skin homografts was examined. Mousestrain combinations with strong (C57BL-C3H/He) and with weaker (A-C3H/He) differences at the H-2 histocompatibility locus were used.
In previous experiments (to be published) it was found possible to modify the antigenic character of skin grafts by in vitro treatment prior to transplantation; thus rejection was obtained of syngeneic skin grafts previously incubated with
